EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 30 / Numéro 4 (Avril 2014) Med Sci (Paris), 30 4 (2014) 415-421 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 30, Numéro 4, Avril 2014
Page(s) 415 - 421
Section Microenvironnements tumoraux : conflictuels et complémentaires
DOI https://doi.org/10.1051/medsci/20143004016
Publié en ligne 5 mai 2014
  1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007 ; 6 : 273–286. [CrossRef] [PubMed] [Google Scholar]
  2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 ; 350 : 2335–2342. [CrossRef] [PubMed] [Google Scholar]
  3. Al-Husein B, Abdalla M, Trepte M, et al. Antiangiogenic therapy for cancer: an update. Pharmacotherapy 2012 ; 32 : 1095–1111. [CrossRef] [PubMed] [Google Scholar]
  4. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011 ; 473 : 298–307. [CrossRef] [PubMed] [Google Scholar]
  5. Farnsworth RH, Lackmann M, Achen MG, Stacker SA. Vascular remodeling in cancer. Oncogene 2013 ; doi : 10.1038/onc.2013.304. [Google Scholar]
  6. Chandel NS, Maltepe E, Goldwasser E, et al. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 1998 ; 95 : 11715–11720. [CrossRef] [Google Scholar]
  7. Bensimon J. Le switch angiogénique ou comment réveiller les cellules tumorales dormantes. Med Sci (Paris) 2012 ; 28 : 1069–1071. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  8. Tertil M, Jozkowicz A, Dulak J. Oxidative stress in tumor angiogenesis–therapeutic targets. Curr Pharm Des 2010 ; 16 : 3877–3894. [CrossRef] [PubMed] [Google Scholar]
  9. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 2011 ; 71 : 2411–2416. [CrossRef] [PubMed] [Google Scholar]
  10. Creagan ET, Moertel CG, O’Fallon JR, et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979 ; 301 : 687–690. [CrossRef] [PubMed] [Google Scholar]
  11. Laleu B, Gaggini F, Orchard M, et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem 2010 ; 53 : 7715–7730. [CrossRef] [PubMed] [Google Scholar]
  12. Bonner MY, Arbiser JL. Targeting NADPH oxidases for the treatment of cancer and inflammation. Cell Mol Life Sci 2012 ; 69 : 2435–2442. [CrossRef] [PubMed] [Google Scholar]
  13. Gray SP, Di Marco E, Okabe J, et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 2013 ; 127 : 1888–1902. [CrossRef] [PubMed] [Google Scholar]
  14. Ushio-Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc Res 2006 ; 71 : 226–235. [CrossRef] [PubMed] [Google Scholar]
  15. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res 2011 ; 21 : 103–115. [CrossRef] [PubMed] [Google Scholar]
  16. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007 ; 87 : 245–313. [CrossRef] [PubMed] [Google Scholar]
  17. Guichard C, Pedruzzi E, Fay M, et al. Les Nox/Duox : une nouvelle famille de NADPH oxydases. Med Sci (Paris) 2006 ; 22 : 953–959. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  18. Lambeth JD, Kawahara T, Diebold B. Regulation of Nox and Duox enzymatic activity and expression. Free Radic Biol Med 2007 ; 43 : 319–331. [CrossRef] [PubMed] [Google Scholar]
  19. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004 ; 4 : 181–189. [CrossRef] [PubMed] [Google Scholar]
  20. Gianni D, DerMardirossian C, Bokoch GM. Direct interaction between Tks proteins and the N-terminal proline-rich region (PRR) of NoxA1 mediates Nox1-dependent ROS generation. Eur J Cell Biol 2011 ; 90 : 164–171. [CrossRef] [PubMed] [Google Scholar]
  21. Chatterjee S, Feinstein SI, Dodia C, et al. Peroxiredoxin 6 phosphorylation and subsequent phospholipase A2 activity are required for agonist-mediated activation of NADPH oxidase in mouse pulmonary microvascular endothelium and alveolar macrophages. J Biol Chem 2011 ; 286 : 11696–11706. [CrossRef] [PubMed] [Google Scholar]
  22. Thakur S, Du J, Hourani S, et al. Inactivation of adenosine A2A receptor attenuates basal and angiotensin II-induced ROS production by Nox2 in endothelial cells. J Biol Chem 2010 ; 285 : 40104–40113. [CrossRef] [PubMed] [Google Scholar]
  23. Garrido-Urbani S, Jemelin S, Deffert C, et al. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARalpha mediated mechanism. PLoS One 2011 ; 6 : e14665. [CrossRef] [PubMed] [Google Scholar]
  24. Frey RS, Ushio-Fukai M, Malik AB. NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology. Antioxid Redox Signal 2009 ; 11 : 791–810. [CrossRef] [PubMed] [Google Scholar]
  25. Shinohara M, Shang WH, Kubodera M, et al. Nox1 redox signaling mediates oncogenic Ras-induced disruption of stress fibers and focal adhesions by down-regulating Rho. J Biol Chem 2007 ; 282 : 17640–17648. [CrossRef] [PubMed] [Google Scholar]
  26. Shinohara M, Adachi Y, Mitsushita J, et al. Reactive oxygen generated by NADPH oxidase 1 (Nox1) contributes to cell invasion by regulating matrix metalloprotease-9 production and cell migration. J Biol Chem 2010 ; 285 : 4481–4488. [CrossRef] [PubMed] [Google Scholar]
  27. Sadok A, Bourgarel-Rey V, Gattacceca F, et al. Nox1-dependent superoxide production controls colon adenocarcinoma cell migration. Biochim Biophys Acta 2008 ; 1783 : 23–33. [CrossRef] [PubMed] [Google Scholar]
  28. Kobayashi S, Nojima Y, Shibuya M, Maru Y. Nox1 regulates apoptosis and potentially stimulates branching morphogenesis in sinusoidal endothelial cells. Exp Cell Res 2004 ; 300 : 455–462. [CrossRef] [PubMed] [Google Scholar]
  29. Chen F, Qian LH, Deng B, et al. Resveratrol protects vascular endothelial cells from high glucose-induced apoptosis through inhibition of NADPH oxidase activation-driven oxidative stress. CNS Neurosci Ther 2013 ; 19 : 675–681. [CrossRef] [PubMed] [Google Scholar]
  30. Ushio-Fukai M, Tang Y, Fukai T, et al. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res 2002 ; 91 : 1160–1167. [CrossRef] [PubMed] [Google Scholar]
  31. Ikeda S, Yamaoka-Tojo M, Hilenski L, et al. IQGAP1 regulates reactive oxygen species-dependent endothelial cell migration through interacting with Nox2. Arterioscler Thromb Vasc Biol 2005 ; 25 : 2295–2300. [CrossRef] [PubMed] [Google Scholar]
  32. Ushio-Fukai M. VEGF signaling through NADPH oxidase-derived ROS. Antioxid Redox Signal 2007 ; 9 : 731–739. [CrossRef] [PubMed] [Google Scholar]
  33. Schroder K, Schutz S, Schloffel I, et al. Hepatocyte growth factor induces a proangiogenic phenotype and mobilizes endothelial progenitor cells by activating Nox2. Antioxid Redox Signal 2011 ; 15 : 915–923. [CrossRef] [PubMed] [Google Scholar]
  34. Ago T, Kitazono T, Ooboshi H, et al. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 2004 ; 109 : 227–233. [CrossRef] [PubMed] [Google Scholar]
  35. Bhandarkar SS, Jaconi M, Fried LE, et al. Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J Clin Invest 2009 ; 119 : 2359–2365. [PubMed] [Google Scholar]
  36. Petry A, Djordjevic T, Weitnauer M, et al. NOX2 and NOX4 mediate proliferative response in endothelial cells. Antioxid Redox Signal 2006 ; 8 : 1473–1484. [CrossRef] [PubMed] [Google Scholar]
  37. Mochizuki T, Furuta S, Mitsushita J, et al. Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene 2006 ; 25 : 3699–3707. [CrossRef] [PubMed] [Google Scholar]
  38. Schroder K, Zhang M, Benkhoff S, et al. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res 2012 ; 110 : 1217–1225. [CrossRef] [PubMed] [Google Scholar]
  39. Fried L, Arbiser JL. The reactive oxygen-driven tumor: relevance to melanoma. Pigment Cell Melanoma Res 2008 ; 21 : 117–122. [CrossRef] [PubMed] [Google Scholar]
  40. Maraldi T, Prata C, Vieceli Dalla Sega F, et al. NAD(P)H oxidase isoform Nox2 plays a prosurvival role in human leukaemia cells. Free Radic Res 2009 ; 43 : 1111–1121. [CrossRef] [PubMed] [Google Scholar]
  41. Peshavariya H, Dusting GJ, Jiang F, et al. NADPH oxidase isoform selective regulation of endothelial cell proliferation and survival. Naunyn Schmiedebergs Arch Pharmacol 2009 ; 380 : 193–204. [CrossRef] [PubMed] [Google Scholar]
  42. Azzi S, Gavard J. Vaisseaux sanguins et tumeurs ou l’art du dialogue. Med Sci (Paris) 2014 ; 30 : 408–414. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  43. Hasmim M, Messai Y, Zaeem M, Chouaib S. L’hypoxie tumorale : un déterminant clé de la réactivité stromale et de la réponse antitumorale. Med Sci (Paris) 2014 ; 30 : 422–428. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.